Opinion/decision on a Paediatric investigation plan (PIP): Opdualag, nivolumab,relatlimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Neoplasms benign, malignant and

Opinion/decision on a Paediatric investigation plan (PIP): Opdualag, nivolumab,relatlimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0169/2024